Bloodstream Infections in Kids Significantly Reduced With Quality Improvement Initiatives
Bloodstream infections associated with catheters can be significantly reduced through quality improvement efforts, possibly leading to better health outcomes and lives saved, decreased stays at the hospital and related costs, according to a new study.
The Cincinnati Childrens
"We were able to reduce the incidence of bloodstream infections after implementing a central line insertion and maintenance bundle, said Derek S. Wheeler, MD, a critical care physician at Cincinnati Childrens and the studys lead author. "This bundle emphasizes full sterile barrier precautions and chlorhexidine skin preparation during insertion, as well as daily discussion of catheter necessity and meticulous site and tubing care. Wheeler is also an assistant professor of clinical pediatrics at the University of Cincinnati College of Medicine.
The study will be presented at 7 p.m. ET Monday, May 3 at the annual Pediatric Academic Societies (PAS) meeting in
The study is one of two presented by Wheeler and colleagues this year at PAS that deal with catheter-associated bloodstream infections. The second study shows that a hospital-wide quality improvement collaborative resulted in a significant reduction in the incidence rate, from a baseline of 3.0 per 1,000 line days to less than 1.0 per 1,000 line days.
The collaborative approach included hospital-wide implementation of the same central line insertion and maintenance bundle on three critical care units, one oncology unit, one bone marrow transplant unit, and general medical/surgical units.
Catheter-associated bloodstream infections (CA-BSI) comprise the vast majority of hospital-acquired BSI in pediatric patients and are associated with increased length of stay (LOS), hospital costs and mortality.
Wheeler conducted the study in collaboration with researchers from Nationwide Childrens Hospital in
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.
Heavy social media use linked to depression
August 31, 2026
U.S. News and World Report, Yahoo! News, MSN, USA Today and other national media highlight a new study by the University of Cincinnati and Northwestern University that found a correlation between heavy social media use and depression in adults.